• More than 1 million doses of ROTATEQ^® (rotavirus vaccine, live, oral pentavalent) are expected to be distributed by the end of 2009, representing a $75 million commitment for Merck.
• We are aiming for an 82-84 percent vaccination rate with ROTATEQ by the end of 2009.

The content on this page was last modified on September 15, 2009.

Merck & Co., Inc., Whitehouse Station, NJ, USA, and Schering-Plough Corporation, Kenilworth, NJ, USA, are now one company. We have combined our global operations under the name Merck & Co., Inc. We are working to update our corporate responsibility Web site to reflect our new, combined, global organization.